Novozymes (SWX:NZYMB) - Stock Price, News & Analysis

NZYMB Stock Overview

NZYMB fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	3/6
Financial Health	4/6
Dividends	3/6

Rewards

Earnings are forecast to grow 17.52% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Has a high level of debt

Novozymes A/S Competitors

EMS-CHEMIE HOLDING

SWX:EMSN

CHF16.7b

Givaudan

SWX:GIVN

CHF37.0b

Sika

SWX:SIKA

CHF41.6b

Clariant

SWX:CLN

CHF4.3b

Price History & Performance

Summary of all time highs, changes and price drops for Novozymes
Historical stock prices
Current Share Price	kr.45.21
52 Week High	kr.0
52 Week Low	kr.0
Beta	0.48
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	0.022%
5 Year Change	-3.93%
Change since IPO	3.81%

Recent updates

Shareholder Returns

	NZYMB	CH Chemicals	CH Market
7D	0%	0.7%	2.0%
1Y	0%	8.0%	-2.8%

Return vs Industry: NZYMB underperformed the Swiss Chemicals industry which returned 8% over the past year.

Return vs Market: NZYMB exceeded the Swiss Market which returned -2.8% over the past year.

Price Volatility

Is NZYMB's price volatile compared to industry and market?
NZYMB volatility
NZYMB Average Weekly Movement	0%
Chemicals Industry Average Movement	3.0%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	7.3%
10% least volatile stocks in CH Market	1.9%

Stable Share Price: NZYMB has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NZYMB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1925	6,577	Ester Baiget	www.novozymes.com

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Novozymes A/S Fundamentals Summary

How do Novozymes's earnings and revenue compare to its market cap?
NZYMB fundamental statistics
Market cap	CHF23.65b
Earnings (TTM)	CHF396.90m
Revenue (TTM)	CHF2.35b

59.6x

P/E Ratio

10.1x

P/S Ratio

Is NZYMB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NZYMB income statement (TTM)
Revenue	kr.17.90b
Cost of Revenue	kr.8.18b
Gross Profit	kr.9.72b
Other Expenses	kr.6.70b
Earnings	kr.3.02b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 28, 2024

Earnings per share (EPS)	6.51
Gross Margin	54.32%
Net Profit Margin	16.89%
Debt/Equity Ratio	51.6%

How did NZYMB perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

88%

Payout Ratio

Does NZYMB pay a reliable dividends?

See NZYMB dividend history and benchmarks

When do you need to buy NZYMB by to receive an upcoming dividend?
Novozymes dividend dates
Ex Dividend Date	May 01 2024
Dividend Pay Date	May 03 2024
Days until Ex dividend	6 days
Days until Dividend pay date	8 days

Does NZYMB pay a reliable dividends?

See NZYMB dividend history and benchmarks

NZYMB Stock Overview

Rewards

Risk Analysis

Novozymes A/S Competitors

SWX:EMSN

CHF16.7b

SWX:GIVN

CHF37.0b

SWX:SIKA

CHF41.6b

SWX:CLN

CHF4.3b

Price History & Performance

Recent News & Updates

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Recent updates

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings released

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

New minor risk - Dividend sustainability

Second quarter 2023 earnings released: EPS: kr.2.19 (vs kr.2.92 in 2Q 2022)

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.7% yield

Independent Chairman recently bought CHF135k worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report First Half, 2023 Results on Aug 09, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

Less than half of directors are independent

First quarter 2021 earnings released

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Upcoming Dividend of kr.5.25 Per Share

Novozymes A/S Announces Executive Appointments, Effective April 2021

Full year 2020 earnings released

Revenue misses expectations

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million